Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure–activity relationships for substituted 2-aryl-1-[ N -(methyl)- N -(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes
作者:Paul E Finke、Laura C Meurer、Bryan Oates、Sander G Mills、Malcolm MacCoss、Lorraine Malkowitz、Martin S Springer、Bruce L Daugherty、Sandra L Gould、Julie A DeMartino、Salvatore J Siciliano、Anthony Carella、Gwen Carver、Karen Holmes、Renee Danzeisen、Daria Hazuda、Joseph Kessler、Janet Lineberger、Michael Miller、William A Schleif、Emilio A Emini
DOI:10.1016/s0960-894x(00)00639-9
日期:2001.1
(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2,3-dihydrobenzthiophene-3,4'-piperidin-1'-yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16. X=H, 3-F, 3-Cl, 3-Me). (C) 2001 Published by Elsevier Science Ltd.
(2S)-2-(3,4-二氯苯基)-1-[N-(甲基)-N-(苯基亚砜)氨基]-4-[螺(2,3-二氢苯并噻吩-3,4'-哌啶-1'-基)]丁烷 S-氧化物 (3) 已被鉴定为一种具有强效 CCR5 拮抗活性的先导结构化合物,其 IC50 值为 35 nM。本文中,我们描述了针对 C-2 苯基片段的需求和优化的结构-活性关系研究。研究发现,苯基对于 CCR5 拮抗活性至关重要,取代基仅限于在 3 位引入小型基团(如 13 和 16,当 X=H、3-F、3-Cl、3-Me 时)。(C) 2001 Elsevier Science Ltd. 出版。